Animal models of cisplatin-induced neuropathic pain

Abstract

Cisplatin chemotherapy has been used as the main treatment for different types of cancer. However, cisplatin chemotherapy-induced peripheral neuropathic pain (CIPNP) seriously affects the treatment process and quality of life of patients. In addition, it impacts the underlying mechanism and prevention and treatment strategies, indicating that drug selection and efficacy evaluation need to be further investigated. Furthermore, an animal model that is more consistent with the pathological mechanism needs to be developed. In this study, we describe and discuss the methods of developing and detecting CIPNP models in rats and mice induced by cisplatin chemotherapy. The aim was to improve the modeling rate and develop animal models that are more consistent with the developmental pattern of the disease. In addition, the study provides ideal reference animal models for clinical research and drug discovery and development.

Keywords

animal models / chemotherapy / cisplatin / peripheral neuropathic pain

References

[1] Bagher AM, Binmahfouz LS, Shaik RA, Eid BG. Cannabinoid receptor 1 positive allosteric modulator (GAT229) attenuates cisplatin-induced neuropathic pain in mice. Saudi Pharm J. 2023; 31(2): 255-264.

[2] Hershman DL, Lacchetti C, Dworkin RH, et al. Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol. 2014; 32(18): 1941-1967.

[3] Alberti P. Platinum-drugs induced peripheral neurotoxicity: clinical course and preclinical evidence. Expert Opin Drug Metab Toxicol. 2019; 15(6): 487-497.

[4] Al Moundhri MS, Al-Salam S, Al Mahrouqee A, Beegam S, Ali BH. The effect of curcumin on oxaliplatin and cisplatin neurotoxicity in rats: some behavioral, biochemical, and histopathological studies. J Med Toxicol. 2013; 9(1): 25-33.

[5] Li Y, Kim WM, Kim SH, et al. Prostaglandin D2 contributes to cisplatin-induced neuropathic pain in rats via DP2 receptor in the spinal cord. Korean J Pain. 2021; 34(1): 27-34.

[6] Kim YO, Song JA, Kim WM, Yoon MH. Antiallodynic effect of intrathecal Korean red ginseng in cisplatin-induced neuropathic pain rats. Pharmacology. 2020; 105(3-4): 173-180.

[7] Lee KH, Rhee KH. ANTI-NOCICEPTIVE EFFECT OF AGRIMONIA EUPATORIA EXTRACT ON A CISPLATIN-INDUCED NEUROPATHIC MODEL. Afr J Tradit Complement Altern Med. 2016; 13(5): 139-144.

[8] Kuai CP, Ju LJ, Hu PP, Huang F. Corydalis saxicola alkaloids attenuate cisplatin-induced neuropathic pain by reducing loss of IENF and blocking TRPV1 activation. Am J Chin Med. 2020; 48(2): 407-428.

[9] Guindon J, Lai Y, Takacs SM, Bradshaw HB, Hohmann AG. Alterations in endocannabinoid tone following chemotherapy-induced peripheral neuropathy: effects of endocannabinoid deactivation inhibitors targeting fatty-acid amide hydrolase and monoacylglycerol lipase in comparison to reference analgesics following cisplatin treatment. Pharmacol Res. 2013; 67(1): 94-109.

[10] Shahid M, Subhan F, Ahmad N, Sewell RDE. Efficacy of a topical gabapentin gel in a cisplatin paradigm of chemotherapy-induced peripheral neuropathy. BMC Pharmacol Toxicol. 2019; 20(1): 51.

[11] Akbar S, Subhan F, Shahid M, et al. 6-Methoxyflavanone abates cisplatin-induced neuropathic pain apropos anti-inflammatory mechanisms: a behavioral and molecular simulation study. Eur J Pharmacol. 2020; 5(872): 172972.

[12] Shahid M, Subhan F, Ahmad N, Sewell RDE. The flavonoid 6-methoxyflavone allays cisplatin-induced neuropathic allodynia and hypoalgesia. Biomed Pharmacother. 2017; 95: 1725-1733.

[13] Moetamani-Ahmadi M, Mahmoud Ahmadzadeh A, Alaei M, et al. Pegylated nanoliposomal cisplatin ameliorates chemotherapy-induced peripheral neuropathy. Int J Pharm. 2024; 5(652): 123839.

[14] Ahmad N, Subhan F, Islam NU, Shahid M, Rahman FU, Sewell RDE. Gabapentin and its salicylaldehyde derivative alleviate allodynia and hypoalgesia in a cisplatin-induced neuropathic pain model. Eur J Pharmacol. 2017; 5(814): 302-312.

[15] Bilir-Yildiz B, Sunay FB, Yilmaz HF, Bozkurt-Girit O. Low-intensity low-frequency pulsed ultrasound ameliorates sciatic nerve dysfunction in a rat model of cisplatin-induced peripheral neuropathy. Sci Rep. 2022; 12(7): 8125.

[16] Authier N, Gillet JP, Fialip J, Eschalier A, Coudore F. An animal model of nociceptive peripheral neuropathy following repeated cisplatin injections. Exp Neurol. 2003; 182(1): 12-20.

[17] Quiñonez-Bastidas GN, Palomino-Hernández O, López-Ortíz M, et al. Antiallodynic effect of PhAR-DBH-me involves cannabinoid and TRPV1 receptors. Pharmacol Res Perspect. 2020; 8(5): e00663.

[18] Cata JP, Weng HR, Dougherty PM. Behavioral and electrophysiological studies in rats with cisplatin-induced chemoneuropathy. Brain Res. 2008; 16(1230): 91-98.

[19] Vera G, Chiarlone A, Cabezos PA, Pascual D, Martín MI, Abalo R. WIN 55,212-2 prevents mechanical allodynia but not alterations in feeding behaviour induced by chronic cisplatin in the rat. Life Sci. 2007; 81(6): 468-479.

[20] Paniagua N, Goicoechea C, Abalo R, et al. May a sigma-1 antagonist improve neuropathic signs induced by cisplatin and vincristine in rats? Eur J Pain. 2019; 23(3): 603-620.

[21] Onk D, Mammadov R, Suleyman B, et al. The effect of thiamine and its metabolites on peripheral neuropathic pain induced by cisplatin in rats. Exp Anim. 2018; 67(2): 259-269.

[22] Boyle FM, Beatson C, Monk R, Grant SL, Kurek JB. The experimental neuroprotectant leukaemia inhibitory factor (LIF) does not compromise antitumour activity of paclitaxel, cisplatin and carboplatin. Cancer Chemother Pharmacol. 2001; 48(6): 429-434.

[23] Mahmoud HA, Horany HEE, Aboalsoud M, Abd-Ellatif RN, Sheikh AAE, Aboalsoud A. Targeting oxidative stress, autophagy, and apoptosis by quercetin to ameliorate cisplatin-induced peripheral neuropathy in rats. J Microsc Ultrastruct. 2023; 11(2): 107-114.

[24] Ta LE, Low PA, Windebank AJ. Mice with cisplatin and oxaliplatin-induced painful neuropathy develop distinct early responses to thermal stimuli. Mol Pain. 2009; 26(5): 9.

[25] Zhang J, Junigan JM, Trinh R, Kavelaars A, Heijnen CJ, Grace PM. HDAC6 inhibition reverses cisplatin-induced mechanical hypersensitivity via Tonic Delta opioid receptor signaling. J Neurosci. 2022; 42(42): 7862-7874.

[26] Ma X, Chen Y, Li XC, et al. Spinal neuronal GRK2 contributes to preventive effect by Electroacupuncture on cisplatin-induced peripheral neuropathy in mice. Anesth Analg. 2022; 134(1): 204-215.

[27] Ruan Y, Jin X, Ji H, et al. Water extract of Notopterygium incisum alleviates cold allodynia in neuropathic pain by regulation of TRPA1. J Ethnopharmacol. 2023; 6(305): 116065.

[28] Becker G, Fialho MFP, Brusco I, Oliveira SM. Kinin B1 and B2 receptors contribute to cisplatin-induced painful peripheral neuropathy in male mice. Pharmaceutics. 2023; 15(3): 852.

[29] Cataldo G, Erb SJ, Lunzer MM, et al. The bivalent ligand MCC22 potently attenuates hyperalgesia in a mouse model of cisplatin-evoked neuropathic pain without tolerance or reward. Neuropharmacology. 2019; 1(158): 107598.

[30] Laumet G, Edralin JD, Dantzer R, Heijnen CJ, Kavelaars A. Cisplatin educates CD8+ T cells to prevent and resolve chemotherapy-induced peripheral neuropathy in mice. Pain. 2019; 160(6): 1459-1468.

[31] Inyang KE, George SR, Laumet G. The μ-δ opioid heteromer masks latent pain sensitization in neuropathic and inflammatory pain in male and female mice. Brain Res. 2021; 1756(1): 147298.

[32] Shim HS, Bae C, Wang J, et al. Peripheral and central oxidative stress in chemotherapy-induced neuropathic pain. Mol Pain. 2019; 15: 98.

[33] Park HJ, Stokes JA, Pirie E, Skahen J, Shtaerman Y, Yaksh TL. Persistent hyperalgesia in the cisplatin-treated mouse as defined by threshold measures, the conditioned place preference paradigm, and changes in dorsal root ganglia activated transcription factor 3: the effects of gabapentin, ketorolac, and etanercept. Anesth Analg. 2013; 116(1): 224-231.

[34] Woller SA, Corr M, Yaksh TL. Differences in cisplatin-induced mechanical allodynia in male and female mice. Eur J Pain. 2015; 19(10): 1476-1485.

[35] Chiou CT, Wang KC, Yang YC, et al. Liu Jun Zi Tang-a potential, multi-herbal complementary therapy for chemotherapy-induced neurotoxicity. Int J Mol Sci. 2018; 19(4): 1258.

[36] Meng J, Qiu S, Zhang L, You M, Xing H, Zhu J. Berberine alleviate cisplatin-induced peripheral neuropathy by modulating inflammation signal via TRPV1. Front Pharmacol. 2022; 26(12): 774795.

[37] Lessans S, Lassiter CB, Carozzi V, et al. Global transcriptomic profile of dorsal root ganglion and physiological correlates of cisplatin-induced peripheral neuropathy. Nurs Res. 2019; 68: 145-155.

[38] Akhtar S, Abbas M, Naeem K, Faheem M, Nadeem H, Mehmood A. Benzimidazole derivative ameliorates opioid-mediated tolerance during anticancer- induced neuropathic pain in mice. Anticancer Agents Med Chem. 2021; 21(3): 365-371.

[39] Marcus DJ, Zee M, Hughes A, et al. Tolerance to the antinociceptive effects of chronic morphine requires c-Jun N-terminal kinase. Mol Pain. 2015; 12(11): 34.

[40] Sepulveda DE, Morris DP, Raup-Konsavage WM, Sun D, Vrana KE, Graziane NM. Cannabigerol (CBG) attenuates mechanical hypersensitivity elicited by chemotherapy-induced peripheral neuropathy. Eur J Pain. 2022; 26(9): 1950-1966.

[41] Nachnani R, Sepulveda DE, Booth JL, et al. Chronic Cannabigerol as an effective therapeutic for cisplatin-induced neuropathic pain. Pharmaceuticals (Basel). 2023; 16(10): 1442.

[42] Guindon J, Deng L, Fan B, Wager-Miller J, Hohmann AG. Optimization of a cisplatin model of chemotherapy-induced peripheral neuropathy in mice: use of vitamin C and sodium bicarbonate pretreatments to reduce nephrotoxicity and improve animal health status. Mol Pain. 2014; 4(10): 56.

[43] Dewaeles E, Carvalho K, Fellah S, et al. Istradefylline protects from cisplatin-induced nephrotoxicity and peripheral neuropathy while preserving cisplatin antitumor effects. J Clin Invest. 2022; 132(22): e152924.

[44] Joseph EK, Levine JD. Comparison of oxaliplatin- and cisplatin-induced painful peripheral neuropathy in the rat. J Pain. 2009; 10(5): 534-541.

[45] Wongtawatchai T, Agthong S, Kaewsema A, Chentanez V. Sex-related differences in cisplatin-induced neuropathy in rats. J Med Assoc Thai. 2009; 92(11): 1485-1491.

[46] Manjavachi MN, Passos GF, Trevisan G, et al. Spinal blockage of CXCL1 and its receptor CXCR2 inhibits paclitaxel-induced peripheral neuropathy in mice. Neuropharmacology. 2019; 151: 136-143.

[47] Bray F, Laversanne M, Sung H, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024; 74: 229-263.

[48] Riely GJ, Wood DE, Ettinger DS, et al. Non-small cell lung cancer, version 4.2024, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2024; 22(4): 249-274.

[49] Hu LY, Mi WL, Wu GC, Wang YQ, Mao-Ying QL. Prevention and treatment for chemotherapy-induced peripheral neuropathy: therapies based on CIPN mechanisms. Curr Neuropharmacol. 2019; 17(2): 184-196.

[50] Casals-Díaz L, Casas C, Navarro X. Changes of voltage-gated sodium channels in sensory nerve regeneration and neuropathic pain models. Restor Neurol Neurosci. 2015; 33(3): 321-334.

[51] Velasco-González R, Coffeen U. Neurophysiopathological aspects of paclitaxel-induced peripheral neuropathy. Neurotox Res. 2022; 40(6): 1673-1689.

[52] Cavalli E, Mammana S, Nicoletti F, Bramanti P, Mazzon E. The neuropathic pain: an overview of the current treatment and future therapeutic approaches. Int J Immunopathol Pharmacol. 2019; 33: 8383.

RIGHTS & PERMISSIONS

2025 The Author(s). Animal Models and Experimental Medicine published by John Wiley & Sons Australia, Ltd on behalf of The Chinese Association for Laboratory Animal Sciences.